The hyperglycemia‐reducing effect of silibinin in the animal diabetes model induced by STZ can be explained by factors such as residual pancreatic function, a direct increase in insulin secretion from Langerhans beta cells, mitigating insulin resistance, or glycemic control through the gut–brain–liver axis. The gene discussed is INS; the disease is Hyperglycemia.